miRNAs as molecular biomarkers for prostate cancer

Donatella Coradduzza; Tatiana Solinas; Francesca Balzano; Nicola Culeddu; Niccolò Rossi; Sara Cruciani; Emanuela Azara; Margherita Maioli; Angelo Zinellu; Maria Rosaria De Miglio; Massimo Madonia; Mario Falchi; Ciriaco Carru

doi:10.1016/j.jmoldx.2022.05.005

miRNAs as molecular biomarkers for prostate cancer

Donatella Coradduzza, Tatiana Solinas, Francesca Balzano, Nicola Culeddu, Niccolò Rossi, Sara Cruciani, Emanuela Azara, Margherita Maioli, Angelo Zinellu, Maria Rosaria De Miglio, Massimo Madonia, Mario Falchi, Ciriaco Carru

Twin Research & Genetic Epidemiology

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

52 Downloads (Pure)

Abstract

miRNAs are short noncoding RNAs able to regulate specific mRNA stability, thus influencing target gene expression. Disrupted levels of several miRNAs have been associated with prostate cancer (PC), the leading cause of cancer death among men and the fifth leading cause of death worldwide. Herein, we investigated whether miR-145, miR-148, and miR-185 circulating levels in plasma could be used as molecular biomarkers, to allow distinguishing between individuals with benign prostatic hyperplasia, precancerous lesions, and PC. One-hundred and seventy urological clinic patients with suspected PC who underwent prostate biopsy were recruited. Total RNA was isolated from plasma, and TaqMan MicroRNA assays were used to analyze miR-145, miR-185, and miR-148 expression. First, differential miRNA expression among patient groups was evaluated. Then, miRNA levels were combined with clinical assessment outcomes, including results from invasive tests, using multivariate analysis to examine their ability in discriminating among the three patient groups. Our results suggest that miRNA is a promising molecular tool for clinical management of at-risk patients.

Original language	English
Pages (from-to)	1171-1180
Number of pages	10
Journal	JOURNAL OF MOLECULAR DIAGNOSTICS
Volume	24
Issue number	11
Early online date	11 Jul 2022
DOIs	https://doi.org/10.1016/j.jmoldx.2022.05.005
Publication status	Published - 1 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jmoldx.2022.05.005

miRNAs as molecular biomarkers_CORADDUZZA_Publishedonline11July2022_GREEN AAMAccepted author manuscript, 451 KBLicence: CC BY-NC-ND

Cite this

@article{f86e72d1213b4144a5dcf178c22a82f7,

title = "miRNAs as molecular biomarkers for prostate cancer",

abstract = "miRNAs are short noncoding RNAs able to regulate specific mRNA stability, thus influencing target gene expression. Disrupted levels of several miRNAs have been associated with prostate cancer (PC), the leading cause of cancer death among men and the fifth leading cause of death worldwide. Herein, we investigated whether miR-145, miR-148, and miR-185 circulating levels in plasma could be used as molecular biomarkers, to allow distinguishing between individuals with benign prostatic hyperplasia, precancerous lesions, and PC. One-hundred and seventy urological clinic patients with suspected PC who underwent prostate biopsy were recruited. Total RNA was isolated from plasma, and TaqMan MicroRNA assays were used to analyze miR-145, miR-185, and miR-148 expression. First, differential miRNA expression among patient groups was evaluated. Then, miRNA levels were combined with clinical assessment outcomes, including results from invasive tests, using multivariate analysis to examine their ability in discriminating among the three patient groups. Our results suggest that miRNA is a promising molecular tool for clinical management of at-risk patients.",

author = "Donatella Coradduzza and Tatiana Solinas and Francesca Balzano and Nicola Culeddu and Niccol{\`o} Rossi and Sara Cruciani and Emanuela Azara and Margherita Maioli and Angelo Zinellu and {De Miglio}, {Maria Rosaria} and Massimo Madonia and Mario Falchi and Ciriaco Carru",

year = "2022",

month = nov,

day = "1",

doi = "10.1016/j.jmoldx.2022.05.005",

language = "English",

volume = "24",

pages = "1171--1180",

journal = "JOURNAL OF MOLECULAR DIAGNOSTICS",

issn = "1525-1578",

publisher = "Association of Molecular Pathology",

number = "11",

}

TY - JOUR

T1 - miRNAs as molecular biomarkers for prostate cancer

AU - Coradduzza, Donatella

AU - Solinas, Tatiana

AU - Balzano, Francesca

AU - Culeddu, Nicola

AU - Rossi, Niccolò

AU - Cruciani, Sara

AU - Azara, Emanuela

AU - Maioli, Margherita

AU - Zinellu, Angelo

AU - De Miglio, Maria Rosaria

AU - Madonia, Massimo

AU - Falchi, Mario

AU - Carru, Ciriaco

PY - 2022/11/1

Y1 - 2022/11/1

N2 - miRNAs are short noncoding RNAs able to regulate specific mRNA stability, thus influencing target gene expression. Disrupted levels of several miRNAs have been associated with prostate cancer (PC), the leading cause of cancer death among men and the fifth leading cause of death worldwide. Herein, we investigated whether miR-145, miR-148, and miR-185 circulating levels in plasma could be used as molecular biomarkers, to allow distinguishing between individuals with benign prostatic hyperplasia, precancerous lesions, and PC. One-hundred and seventy urological clinic patients with suspected PC who underwent prostate biopsy were recruited. Total RNA was isolated from plasma, and TaqMan MicroRNA assays were used to analyze miR-145, miR-185, and miR-148 expression. First, differential miRNA expression among patient groups was evaluated. Then, miRNA levels were combined with clinical assessment outcomes, including results from invasive tests, using multivariate analysis to examine their ability in discriminating among the three patient groups. Our results suggest that miRNA is a promising molecular tool for clinical management of at-risk patients.

AB - miRNAs are short noncoding RNAs able to regulate specific mRNA stability, thus influencing target gene expression. Disrupted levels of several miRNAs have been associated with prostate cancer (PC), the leading cause of cancer death among men and the fifth leading cause of death worldwide. Herein, we investigated whether miR-145, miR-148, and miR-185 circulating levels in plasma could be used as molecular biomarkers, to allow distinguishing between individuals with benign prostatic hyperplasia, precancerous lesions, and PC. One-hundred and seventy urological clinic patients with suspected PC who underwent prostate biopsy were recruited. Total RNA was isolated from plasma, and TaqMan MicroRNA assays were used to analyze miR-145, miR-185, and miR-148 expression. First, differential miRNA expression among patient groups was evaluated. Then, miRNA levels were combined with clinical assessment outcomes, including results from invasive tests, using multivariate analysis to examine their ability in discriminating among the three patient groups. Our results suggest that miRNA is a promising molecular tool for clinical management of at-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85138715223&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2022.05.005

DO - 10.1016/j.jmoldx.2022.05.005

M3 - Article

SN - 1525-1578

VL - 24

SP - 1171

EP - 1180

JO - JOURNAL OF MOLECULAR DIAGNOSTICS

JF - JOURNAL OF MOLECULAR DIAGNOSTICS

IS - 11

ER -

miRNAs as molecular biomarkers for prostate cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this